Scientific Publications & Presentations

Phase 1 Trial Results for IMA203CD8, a PRAME-Targeted T-cell Receptor (TCR) T-cell Therapy, in Ovarian Cancer

Busse, et. al

Phase 1 Trial Results with PRAME-targeted T-cell Receptor (TCR) T-cell Therapies in Synovial Sarcoma

Araujo, et. al

IMA203CD8 Plain Language Summary

First-in-Human Results With IMA401, a MAGEA4/8-targeted T-cell Receptor-based Bispecific T-cell Engager (TCER), in Recurrent or Refractory Solid Tumors

Wermke, et. al

Patient-level Clinical Response Dynamics in Advanced Melanoma With Anzu-cel, a PRAME-targeted TCR T-cell Therapy

Davar, et. al

Anzu-cel Plain Language Summary

ASCO Annual Meeting 2026
May 29 – June 2, 2026, Chicago, IL, USA

IMA203CD8 PRAME-directed T-cell receptor T-cell therapy in ovarian cancer: results from a phase 1a study

SGO Annual Meeting on Women’s Cancer 2026
April 10-13, 2026, San Juan, Puerto Rico
Taylor, et. al

A Phase 1 Trial of IMA203CD8, a PRAME-directed TCR T-cell Therapy in PRAME-positive Solid Tumors

ESMO Immuno-Oncology Congress 2025
December 10-12, 2025, London, United Kingdom
Busse, et. al

A first-in-human, phase 1 trial of IMA203 PRAME-directed TCR T-cell therapy with PRAME encoding mRNA-4203 in previously treated, unresectable or metastatic cutaneous melanoma or synovial sarcoma (NCT06946225)

SITC 2025
November 5-9, 2025, National Harbor, Maryland, USA
Smithy, et. al

Anzutresgene Autoleucel (IMA203), a PRAME-directed T-cell receptor T-cell therapy, demonstrated broad organ penetration in patients with heavily pretreated advanced or metastatic melanoma in a phase 1 trial

SMR Congress 2025
October 25 – 28, 2025 Amsterdam, the Netherlands
Wermke, et al.

SUPRAME: A phase 3 trial comparing IMA203, an engineered T-cell receptor expressing T-cell therapy (TCR T) vs investigator’s choice in patients with previously treated advanced cutaneous melanoma

ASCO 2025
May 30 – June 3, 2025 Chicago, IL
Wermke, et al.

Phase 1 Clinical Update of IMA203, an Autologous TCR T Targeting PRAME in Patients with PD1 Refractory Metastatic Melanoma

ASCO 2025
May 30 – June 3, 2025 Chicago, IL
Wermke, et al.

T cell receptor discovery for cancer and beyond: in this paper we identify novel SARS-CoV-2-specific TCRs against recently discovered epitopes demonstrating the versality of Immatics’ TCR discovery platform XCEPTOR®.

Description of computational and experimental methods as part of the XPRESIDENT® technology platform that allow identification of true HLA ligands as targets for TCR-based immunotherapies by mass spectrometry.

Immatics scientists and collaborators present functionally empty and peptide-receptive HLA-A*02:01 molecules that enable quick generation of large libraries of peptide-MHC complexes for TCR screening.

A review by two leaders of Immatics’ Cell Therapy CMC Group.

Joint publication by MD Anderson Cancer Center and Immatics demonstrating the capability of Immatics to validate a new target class, RNA-edited pHLA targets.

First publication on the GAPVAC actively personalized vaccine trial conducted by a consortium led by Immatics. The warehouse approach pioneered in GAPVAC was the blueprint for the ongoing ACTolog^® clinical trial by Immatics, which applies the multi-target warehouse approach for the first time in ACT.

First publication on the proprietary IMADetect^® target biomarker screening platform by Immatics as used in all ongoing ACT trials. Immatics uses a unique approach setting the qPCR threshold for each target guided by XPRESIDENT^® mass spectrometry.

The original paper by Toni Weinschenk, Co-founder and Chief Innovation Officer of Immatics on the XPRESIDENT^® target discovery platform.